- Senate passes Drug Quality and Security Act
- Teva launches authorized generic version of Pfizer's Detrol LA
- Reports: ESI may start 'price war' over new hepatitis C drugs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- 21 health industry groups address FDA on proposed changes to generic drug label rules
PITTSBURGH — A federal court in New York has dismissed a lawsuit alleging that Mylan infringed four of Teva Pharmaceutical Industries' patents when it sought Food and Drug Administration approval for a multiple sclerosis drug.
Mylan had filed with the FDA for approval of a generic version of Teva's Copaxone (glatiramer acetate), attracting a patent-infringement suit from Teva alleging that it violated four patents on the drug, according to FDA records. The U.S. District Court for the Southern District of New York has dismissed the case.
Mylan said it would appeal to the Federal Circuit a separate decision at the same district court by a different judge that upheld nine other patents.
Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.